MACC1 as a Prognostic Biomarker for Early-Stage and AFP-Normal Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Xie, Chan ^a,b   Wu, Jueheng ^c   Yun, Jingping ^b   Lai, Jiaming ^d   Yuan, Yunfei ^b   Gao, Zhiliang ^a   Li, Mengfeng ^c,e   Li, Jun ^c   Song, Libing ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; METASTASIS ASSOCIATED IN COLON CANCER 1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METASTASIS ASSOCIATED IN COLON CANCER 1 GENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84878145471     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064235     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
3. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P, (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer 92: 935-941.
4. Puneeta Tandon, Guadalupe Garcia-Tsao, (2009) Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver International 29: 502-510.
5. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, et al. (2008) Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 28: 79-87.
6. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, et al. (2011) MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 31: 777-780.
7. Jiliang Qiu, Pinzhu Huang, Qian Liu, Hong J, Li B, et al. (2011) Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine 9: 166-9176.
8. Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, et al. (2011) Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31: 1141-1145.
9. Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, et al. (2010) MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 30: 3441-3444.
10. Shirahata A, Shinmura K, Kitamura Y, Sakuraba K, Yokomizo K, et al. (2010) MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res 30: 2689-2692.
11. Arlta F, Stein U, (2009) Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41: 2356-2359.
12. Stein U, Walther W, Arlt F, Schwabe H, Smith J, et al. (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature medicine 15: 59-68.
13. Kokoszyńska K, Kryński J, Rychlewski L, Wyrwicz LS, (2009) Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol 56: 317-323.
14. Bhogal RH, Hodson J, Bartlett DC, Weston CJ, Curbishley SM, et al. (2011) Isolation of Primary Human Hepatocytes from Normal and Diseased Liver Tissue: A One Hundred Liver Experience. Plos One 6: e18222.
15. Xie C, Song L-b, Wu J-h, Li J, Yun JP, et al. (2012) Upregulator of Cell Proliferation Predicts Poor Prognosis in Hepatocellular Carcinoma and Contributes to Hepatocarcinogenesis by Downregulating FOXO3a. Plos One 7: e40607.
16. Nagasue N, (1998) Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 5: 7-13.
17. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, et al. (1994) Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 20: 65-71.
18. Llovet JM, Bruix J, (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl): 20-37.
19. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
20. Kaposi-Novak P, Lee J-S, Gòmez-Quiroz L, Coulouarn C, Factor VM, et al. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582-1595.